461 related articles for article (PubMed ID: 33240819)
1. Mutant p53 in Cancer Progression and Targeted Therapies.
Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
Front Oncol; 2020; 10():595187. PubMed ID: 33240819
[No Abstract] [Full Text] [Related]
2. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
3. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.
Schulz-Heddergott R; Moll UM
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29875343
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
5. Regulators of Oncogenic Mutant TP53 Gain of Function.
Yamamoto S; Iwakuma T
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30577483
[TBL] [Abstract][Full Text] [Related]
6. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
[TBL] [Abstract][Full Text] [Related]
7. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
[TBL] [Abstract][Full Text] [Related]
8. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.
Kamath D; Iwakuma T; Bossmann SH
Nanomedicine; 2024 Feb; 56():102732. PubMed ID: 38199451
[TBL] [Abstract][Full Text] [Related]
10. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
Front Oncol; 2021; 11():642603. PubMed ID: 34178628
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
12. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 - Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival.
Alexandrova EM; Marchenko ND
Front Endocrinol (Lausanne); 2015; 6():53. PubMed ID: 25954247
[TBL] [Abstract][Full Text] [Related]
14. Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials.
Nishikawa S; Iwakuma T
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672377
[TBL] [Abstract][Full Text] [Related]
15. Targeting mutant p53 in cancer: the latest insights.
Di Agostino S; Fontemaggi G; Strano S; Blandino G; D'Orazi G
J Exp Clin Cancer Res; 2019 Jul; 38(1):290. PubMed ID: 31277687
[TBL] [Abstract][Full Text] [Related]
16. Tumour-associated mutant p53 drives the Warburg effect.
Zhang C; Liu J; Liang Y; Wu R; Zhao Y; Hong X; Lin M; Yu H; Liu L; Levine AJ; Hu W; Feng Z
Nat Commun; 2013; 4():2935. PubMed ID: 24343302
[TBL] [Abstract][Full Text] [Related]
17. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
Elife; 2015 Aug; 4():. PubMed ID: 26271008
[TBL] [Abstract][Full Text] [Related]
18. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations.
Meng X; Gao JZ; Gomendoza SMT; Li JW; Yang S
Front Med (Lausanne); 2021; 8():737951. PubMed ID: 34671620
[TBL] [Abstract][Full Text] [Related]
20. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
Stein Y; Rotter V; Aloni-Grinstein R
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
